

NOVO NORDISK A S  
Form 6-K  
July 01, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

**JULY 1, 2010**

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_



## Company Announcement

30 June 2010

Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2010

In accordance with Section 6 of the Danish Statutory Order on Issuers Disclosure Obligations, Novo Nordisk is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk as per the end of the month where changes have occurred.

Referring to Company Announcement no 34/2010 dated 28 June 2010, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk as per 30 June 2010.

	<b>Number of</b>		
	<b>shares Nominal value</b>		
	<b>(nominal value</b>	<b>(DKK) Number of votes</b>	
	<b>DKK 1)</b>	<b>(DKK)</b>	
<b>A shares</b>	<b>107,487,200</b>	<b>107,487,200</b>	<b>107,487,200,000</b>
<b>B shares</b>	<b>492,512,800</b>	<b>492,512,800</b>	<b>49,251,280,000</b>

*Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,650 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

Company Announcement no 35 / 2010

Page 1 of 2

<b>Novo Nordisk A/S</b>	Novo Allé	Telephone:	Internet:	CVR Number:
Corporate Communications	2880 Bagsværd Denmark	+45 4444 8888	<a href="http://novonordisk.com">novonordisk.com</a>	24256790
		Telefax:		
		+45 4444 2314		

For further information please contact:

Media:

*Outside North America*  
Mette Kruse Danielsen

Tel: (+45) 4442 3883

[mkd@novonordisk.com](mailto:mkd@novonordisk.com)

Investors:

*Outside North America*  
Klaus Bülow Davidsen

Tel: (+45) 4442 3176

[klda@novonordisk.com](mailto:klda@novonordisk.com)

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471

[krop@novonordisk.com](mailto:krop@novonordisk.com)

*In North America:*

Sean Clements

Tel: (+1) 609 514 8316

[secl@novonordisk.com](mailto:secl@novonordisk.com)

*In North America:*

Hans Rommer

Tel: (+1) 609 919 7937

[hmmm@novonordisk.com](mailto:hmmm@novonordisk.com)

Company Announcement no 35 / 2010

Page 2 of 2

**Novo Nordisk A/S**

Novo Allé

Telephone:

Internet:

CVR Number:

Corporate  
Communications

2880 Bagsværd

+45 4444 8888

novonordisk.com

24256790

Denmark

Telefax:

+45 4444 2314

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: JULY 1, 2010

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer

---